Abstract:Background Circulating tumor cells (CTCs) carry a wealth of information on primary and metastatic tumors critical for enhancing the understanding of the occurrence, progression and metastasis of non-small cell lung cancer (NSCLC). However, the low sensitivity of traditional tumor detection methods limits the application of CTCs in the treatment and disease surveillance of NSCLC. Therefore, CTCs isolation and detection with high sensitivity is highly desired especially for NSCLC patients, which is significant because of high occurrence and mortality. While it is very challenging because of the lower expression of CTC positive biomarkers such as epithelial cell adhesion molecules and cytokeratins (EpCAM and CKs), herein we report a method based on peptide-functionalized magnetic nanoparticles with high CTC capture efficiency, which demonstrates superiority in NSCLC clinical applications. Methods For analysis and comparison of the peptide-functionalized magnetic nanoparticles (TumorFisher, Nanopep Corp.) and the antibody-modified magnetic beads (CellSearch, Janssen Diagnostics, LLC), two NSCLC cell lines, A549 and NCI-H1975 were chosen to measure the binding affinity and capture efficiency. In order to compare the effect of the clinical application of these two detection systems, 7 early stage patients with NSCLC were enrolled in this study. To further explore the clinical utility of CTC counting in different stages, 81 NSCLC patients in stage I–IV were enrolled for CTC enumeration and statistical analysis. Results The binding affinities of the recognition peptide to A549 and NCI-H1975 are 76.7%±11.0% and 70.1%±4.8%, respectively, which is similar with the positive control group (anti-EpCAM antibodies). CTCs were captured in 5/7 (71.4%) of early stage NSCLC patients with NSCLC in TumorFisher system, which is higher than CellSearch, and the false negative of TumorFisher is much lower than CellSearch. In a larger clinical cohort, the CTC numbers of NSCLC patients varied in different stages and the overall detection rate of TumorFisher was 59/81 (72.8%), with the similar proportion in stage I (21/29, 72.4%), II (17/22, 77.3%) and III (16/21, 76.2%). Conclusions Highly efficient CTC isolation technique based on peptide-magnetic nanoparticles was firstly applied in NSCLC patients. Compared with the antibody-based the technique, the higher CTC detection rates (71.4%) in NSCLC patient blood samples were demonstrated for the patients in different stages, I–IV, especially in early stages. This indicates the feasibility of the clinical utility of this new technique in early stage screening, prognosis and therapy evaluation of NSCLC.

High-throughput viable circulating tumor cell isolation using tapered-slit membrane filter-based chipsets in the differential diagnosis of ovarian tumors

Evaluation of the Diagnostic Value of Circulating Tumor Cells with CytoSorter® CTC Capture System in Patients with Breast Cancer.

Diagnostic Value of HE4+ Circulating Tumor Cells in Patients with Suspicious Ovarian Cancer

Detection of Circulating Tumor Cells and Evaluation of Epithelial-Mesenchymal Transition Patterns of Circulating Tumor Cells in Ovarian Cancer

Analysis of Circulating Tumor Cells in Ovarian Cancer and Their Clinical Value As a Biomarker

An Automatic Platform Based on Nanostructured Microfluidic Chip for Isolating and Identification of Circulating Tumor Cells

Establishment of an Optimized CTC Detection Model Consisting of EpCAM,MUC1 and WT1 in Epithelial Ovarian Cancer and Its Correlation with Clinical Characteristics

Platelet RNA Enables Accurate Detection of Ovarian Cancer: an Intercontinental, Biomarker Identification Study.

Purification of Circulating Tumor Cells Based on Multiantibody-Modified Magnetic Nanoparticles and Molecular Analysis Toward Epithelial Ovarian Cancer Detection.

A Novel Automatic Platform Based on Nanostructured Microfluidic Chip for Isolating and Identification of Circulating Tumor Cells

Combined Detection and Subclass Characteristics Analysis of CTCs and CTECs by SE-iFISH in Ovarian Cancer

Circulating tumor cells help differentiate benign ovarian lesions from cancer before surgery: A literature review and proof of concept study using flow cytometry with fluorescence imaging

Improvement of Specific Detection of Circulating Tumor Cells Using Combined CD45 Staining and Fluorescence in Situ Hybridization

The Detection of Stem-Like Circulating Tumor Cells Could Increase the Clinical Applicability of Liquid Biopsy in Ovarian Cancer

Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses

Abstract A32: Novel biomarker algorithm to improve the differential diagnosis of ovarian cancer with in patients with ovarian tumor.

A label-free microfluidic chip for the highly selective isolation of single and cluster CTCs from breast cancer patients

Feasibility of Circulating Tumor Cells (ctcs) Combined with Medical Imaging Examinations to Screen for Cancer and Improve Diagnosis in Non-Metastatic Invasive Breast Cancer Patients: a Cohort Study

Double spiral chip-embedded micro-trapezoid filters (SMT filters) for the sensitive isolation of CTCs of prostate cancer by spectral detection

Highly Sensitive Enumeration of Circulating Tumor Cells in Lung Cancer Patients Using a Size-Based Filtration Microfluidic Chip.

Efficient Isolation and Quantification of Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Using Peptide-Functionalized Magnetic Nanoparticles.